STARBOARD Triplet Hits 33-Month PFS in BRAF-Mutant Melanoma
STARBOARD shows 33.0 months median PFS and 70% ORR for encorafenib-binimetinib-pembrolizumab in BRAF V600-mutant melanoma, redefining first-line choices.
Topic
Binimetinib
Topic
Topic
Topic
STARBOARD shows 33.0 months median PFS and 70% ORR for encorafenib-binimetinib-pembrolizumab in BRAF V600-mutant melanoma, redefining first-line choices.